Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
暂无分享,去创建一个
S. Rashid | E. Yahya | Mateusz Kciuk | R. Kontek | M. Iqbal | M. A. Abdulsamad | A. A. Allaq | Summya Rashid | Mateusz Kciuk | Esam Bashir Yahya | Montaha Mohamed Ibrahim Mohamed | Muhammad Omer Iqbal | Renata Kontek | Muhanad A. Abdulsamad | Abdulmutalib A. Allaq | Montaha Mohamed Ibrahim Mohamed | M. Kciuk | A. Allaq
[1] C. Burton,et al. Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. , 2023, Molecular therapy oncolytics.
[2] R. Drozda,et al. PD-1/PD-L1 and DNA Damage Response in Cancer , 2023, Cells.
[3] S. Oka,et al. Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele , 2022, Journal of virology.
[4] R. Duran,et al. Tumor response assessment on imaging following immunotherapy , 2022, Frontiers in Oncology.
[5] S. Swaminathan,et al. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy , 2022, Frontiers in Immunology.
[6] P. Pedrazzoli,et al. Store-Operated Ca2+ Entry Is Up-Regulated in Tumour-Infiltrating Lymphocytes from Metastatic Colorectal Cancer Patients , 2022, Cancers.
[7] M. Rahim,et al. Cancer vaccines: past, present and future; a review article , 2022, Discover Oncology.
[8] S. Chupradit,et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons , 2022, Cell Communication and Signaling.
[9] M. D. de Miguel,et al. New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors , 2022, Current Oncology Reports.
[10] Yayi He,et al. Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications , 2022, Chinese medical journal.
[11] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[12] P. Lacal,et al. Clinical Experience with CTLA-4 Blockade for Cancer Immunotherapy: From the Monospecific Monoclonal Antibody Ipilimumab to Probodies and Bispecific Molecules Targeting The Tumor Microenvironment. , 2021, Pharmacological research.
[13] Parisa Sharifi,et al. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. , 2021, Clinical immunology.
[14] Yangqiu Li,et al. TIM-3 in Leukemia; Immune Response and Beyond , 2021, Frontiers in Oncology.
[15] Jibiao Wu,et al. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy , 2021, Frontiers in Pharmacology.
[16] S. Windhorst,et al. Oncogenic activity and cellular functionality of melanoma associated antigen A3. , 2021, Biochemical pharmacology.
[17] M. Górska,et al. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners , 2021, Cancer metastasis reviews.
[18] L. Fashoyin-Aje,et al. Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health , 2021, The oncologist.
[19] A. Frampton,et al. Gene of the month: lymphocyte-activation gene 3 (LAG-3) , 2021, Journal of Clinical Pathology.
[20] J. Eaton,et al. Cancer Vaccines: Promising Therapeutics or an Unattainable Dream , 2021, Vaccines.
[21] N. Bhardwaj,et al. Vaccines for immunoprevention of cancer. , 2021, The Journal of clinical investigation.
[22] N. G. Olaiya,et al. Insights into the Role of Biopolymer Aerogel Scaffolds in Tissue Engineering and Regenerative Medicine , 2021, Polymers.
[23] F. Ciompi,et al. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects , 2021, International journal of molecular sciences.
[24] yang-xin fu,et al. Next-generation cytokines for cancer immunotherapy , 2021, Antibody therapeutics.
[25] Rosalie M Sterner,et al. CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.
[26] E. Yahya,et al. Recent trends in cancer therapy: A review on the current state of gene delivery. , 2021, Life sciences.
[27] L. Fong,et al. Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas. , 2021, Cancer discovery.
[28] M. Adamaki,et al. Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer , 2021, Cancers.
[29] Nader Meskin,et al. Mathematical Models of Cancer and Different Therapies , 2021 .
[30] W. Cho,et al. Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy , 2020, Expert review of clinical pharmacology.
[31] A. Kunnumakkara,et al. Rationalizing the therapeutic potential of apigenin against cancer. , 2020, Life sciences.
[32] Chaoliang He,et al. Biopolymer Immune Implants’ Sequential Activation of Innate and Adaptive Immunity for Colorectal Cancer Postoperative Immunotherapy , 2020, Advanced materials.
[33] E. Yahya,et al. A Review on the Medicinal and Aromatic Plants Growing in Libya and Their Therapeutic Properties. , 2020, International Research Journal of Science and Technology.
[34] M. Lotze,et al. Intrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease , 2020, The Journal of thoracic and cardiovascular surgery.
[35] C. Solinas,et al. Targeting CTLA‐4 in cancer: Is it the ideal companion for PD‐1 blockade immunotherapy combinations? , 2020, International journal of cancer.
[36] H. Nijman,et al. Tumor-infiltrating lymphocytes in the immunotherapy era , 2020, Cellular & Molecular Immunology.
[37] A. Haydon,et al. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma , 2020, Journal for ImmunoTherapy of Cancer.
[38] S. Fu,et al. Wilms' Tumor 1 (WT1): The Vaccine for Cancer. , 2020, Journal of immunotherapy and precision oncology.
[39] E. Yahya,et al. THE CYTOTOXICITY EFFECTS OF OUTER MEMBRANE VESICLES ISOLATED FROM HOSPITAL AND LABORATORY STRAINS OF PSEUDOMONAS AERUGINOSA ON HUMAN KERATINOCYTE CELL LINE , 2020 .
[40] S. M. Toor,et al. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential , 2020, Expert opinion on therapeutic targets.
[41] Qianhong Cen,et al. A review on development of MUC1-based cancer vaccine. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[42] Haidong Dong,et al. Immune resilience in response to cancer therapy , 2020, Cancer Immunology, Immunotherapy.
[43] C. Kai,et al. Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy , 2020, Molecular therapy oncolytics.
[44] S. Rizal,et al. A Review on Revolutionary Natural Biopolymer-Based Aerogels for Antibacterial Delivery , 2020, Antibiotics.
[45] J. Christensen,et al. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy , 2020, British Journal of Cancer.
[46] A. Barati,et al. Current progress in cancer immunotherapy based on natural killer cells , 2020, Cell biology international.
[47] K. Fisher,et al. The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. , 2020, Cytokine & growth factor reviews.
[48] A. Wali,et al. Growth Rate and Antibiotic Sensitivity Effect of Some Natural and Petroleum Based Materials on Staphylococcus aureus , 2020 .
[49] Joe-Marc Chauvin,et al. TIGIT in cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.
[50] Elizabeth L Siegler,et al. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies , 2020, Frontiers in Immunology.
[51] N. G. Olaiya,et al. A Review on Plant Cellulose Nanofibre-Based Aerogels for Biomedical Applications , 2020, Polymers.
[52] C. Robert. A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.
[53] G. de Pouvourville,et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective , 2020, Journal for ImmunoTherapy of Cancer.
[54] Zemin Zhang,et al. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.
[55] L. Tentori,et al. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. , 2020, Pharmacological research.
[56] P. Lacal,et al. Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages. , 2020, Oncology reports.
[57] Yanling Liu,et al. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy , 2020, Cancer Immunology, Immunotherapy.
[58] Thanh Loc Nguyen,et al. Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. , 2020, Biomaterials.
[59] R. Jain,et al. A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.
[60] K. Hargadon. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints , 2020, Clinical and translational medicine.
[61] K. Kunimasa,et al. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges , 2020, International journal of molecular sciences.
[62] Kathe P. Fox,et al. Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data‐Driven Analysis on a Nationwide Cohort , 2020, Clinical pharmacology and therapeutics.
[63] I. Witz,et al. The Tumor Microenvironment , 2012 .
[64] Camille Guillerey,et al. TIGIT as an emerging immune checkpoint , 2019, Clinical and experimental immunology.
[65] J. Sampson,et al. Brain immunology and immunotherapy in brain tumours , 2019, Nature Reviews Cancer.
[66] E. Yahya,et al. Prevalence of Human Papilloma Virus Sub Genotypes following Head and Neck Squamous Cell Carcinomas in Asian Continent, A Systematic Review Article , 2019, Asian Pacific Journal of Cancer Prevention.
[67] J. Chavez,et al. Cytokine Release Syndrome: Current Perspectives , 2019, ImmunoTargets and therapy.
[68] Xiaoshen Zhang,et al. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer , 2019, OncoTargets and therapy.
[69] Michael S. Goldberg,et al. Improving cancer immunotherapy through nanotechnology , 2019, Nature Reviews Cancer.
[70] Akintunde Akinleye,et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.
[71] I. Melero,et al. Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.
[72] Christopher M. Jackson,et al. Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.
[73] Q. Pu,et al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy , 2019, mAbs.
[74] A. Rotte,et al. Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.
[75] D. Kong,et al. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy , 2019, Theranostics.
[76] K. Margolin,et al. Cytokine Therapy. , 2019, Hematology/oncology clinics of North America.
[77] K. Mossman,et al. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? , 2019, Oncoimmunology.
[78] Brian Ruffell,et al. Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.
[79] A. Umar,et al. Cancer prevention and screening: the next step in the era of precision medicine , 2019, npj Precision Oncology.
[80] Rachel S. Riley,et al. Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.
[81] J. Kinet,et al. Calcium signalling in T cells , 2019, Nature Reviews Immunology.
[82] T. Waldmann,et al. Cytokines in the Treatment of Cancer. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[83] Bin Zhou,et al. Oncolytic cancer therapy with a vaccinia virus strain. , 2018, Oncology reports.
[84] T. Waldmann. Cytokines in Cancer Immunotherapy. , 2018, Cold Spring Harbor perspectives in biology.
[85] C. Verrill,et al. An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. , 2018, Cancer research.
[86] J. Feijen,et al. Peptide‐decorated polymeric nanomedicines for precision cancer therapy , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[87] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[88] J. Dou,et al. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[89] M. Sadelain,et al. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[90] A. Mantovani,et al. Cancer Inflammation and Cytokines. , 2018, Cold Spring Harbor perspectives in biology.
[91] F. Zufall,et al. A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity , 2018, The Journal of physiology.
[92] D. Pérez-Ibave,et al. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. , 2018, Cancer epidemiology.
[93] Androulla N. Miliotou,et al. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. , 2018, Current pharmaceutical biotechnology.
[94] Christopher M. Jackson,et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM , 2018, Oncoimmunology.
[95] T. Shi,et al. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints , 2018, International journal of molecular sciences.
[96] D. Bedognetti,et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives , 2018, Front. Immunol..
[97] P. Smolewski,et al. Immune Checkpoint Inhibitors to Treat Malignant Lymphomas , 2018, Journal of immunology research.
[98] Chi Zhang,et al. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy , 2018, Scientific Reports.
[99] H. Yamaue,et al. Cancer Vaccine Therapy Using Carcinoembryonic Antigen - expressing Dendritic Cells generated from Induced Pluripotent Stem Cells , 2018, Scientific Reports.
[100] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[101] R. Salgia,et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.
[102] J. Tavernier,et al. Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. , 2018, Cancer research.
[103] D. Sansom,et al. CTLA-4: a moving target in immunotherapy. , 2018, Blood.
[104] Kwangmo Yang,et al. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells , 2018, PloS one.
[105] R. Vile,et al. Infectious Optimism following the 10th International Oncolytic Virus Meeting , 2017 .
[106] Stephen J. Schuster,et al. Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.
[107] A. Gadducci,et al. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. , 2017, Anticancer research.
[108] D. Karan. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice. , 2017, Vaccine.
[109] M. Honda,et al. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis , 2017, Scientific Reports.
[110] A. Khaled,et al. Cytokines in immunogenic cell death: Applications for cancer immunotherapy , 2017, Cytokine.
[111] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[112] Hui Peng,et al. An epithelial-to-mesenchymal transition-inducing potential of granulocyte macrophage colony-stimulating factor in colon cancer , 2017, Scientific Reports.
[113] F. Marincola,et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. , 2017, European journal of cancer.
[114] Y. Kodera,et al. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials , 2017, Front. Oncol..
[115] Xingchun Gou,et al. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy , 2017, Front. Immunol..
[116] Yuhua Wang,et al. Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[117] K. Shen,et al. Recent progress in GM-CSF-based cancer immunotherapy. , 2017, Immunotherapy.
[118] W. Dougall,et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy , 2017, Immunological reviews.
[119] J. Altomonte,et al. Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil” , 2017, Biomedicines.
[120] D. Lambrechts,et al. Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. , 2017, Developmental cell.
[121] M. Kudo. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials , 2017, Oncology.
[122] H. Heslop,et al. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[123] Yousef Ahmed Fouad,et al. Revisiting the hallmarks of cancer. , 2017, American journal of cancer research.
[124] H. Sultan,et al. Designing therapeutic cancer vaccines by mimicking viral infections , 2017, Cancer Immunology, Immunotherapy.
[125] Connie Y. C. Ma,et al. Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma , 2016 .
[126] H. Fukuhara,et al. Oncolytic virus therapy: A new era of cancer treatment at dawn , 2016, Cancer science.
[127] H. Kohrt,et al. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[128] Ryan M. O’Connell,et al. Genome-Wide CRISPR-Cas9 Screen Identifies MicroRNAs That Regulate Myeloid Leukemia Cell Growth , 2016, PloS one.
[129] J. Banchereau,et al. The Human Vaccines Project: A roadmap for cancer vaccine development , 2016, Science Translational Medicine.
[130] M. Mita,et al. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. , 2016, World journal of methodology.
[131] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[132] Yao Wang,et al. Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report , 2016, Signal Transduction and Targeted Therapy.
[133] Clarke Brian Blackadar,et al. Historical review of the causes of cancer. , 2016, World journal of clinical oncology.
[134] E. Buchbinder,et al. CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.
[135] J. Diallo,et al. Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. , 2015, Trends in cancer.
[136] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[137] J. E. Brewer,et al. NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.
[138] S. Ghafouri-Fard,et al. MAGE-A3: an immunogenic target used in clinical practice. , 2015, Immunotherapy.
[139] L. Zitvogel,et al. Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.
[140] Troy Guthrie,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] Joe-Marc Chauvin,et al. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. , 2015, The Journal of clinical investigation.
[142] Michel Sadelain,et al. The journey from discoveries in fundamental immunology to cancer immunotherapy. , 2015, Cancer cell.
[143] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[144] J. Hackney,et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.
[145] Yang Liu,et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. , 2014, Clinical immunology.
[146] P. Chong,et al. Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide , 2014, Human vaccines & immunotherapeutics.
[147] C. Breitbach,et al. Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.
[148] S. Rosenberg. IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.
[149] N. Agarwal,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[150] S. Rabkin,et al. Oncolytic Viruses and Their Application to Cancer Immunotherapy , 2014, Cancer Immunology Research.
[151] I. Wauters,et al. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer , 2014, Expert opinion on biological therapy.
[152] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[153] D. Lyles,et al. Signaling Pathways in Murine Dendritic Cells That Regulate the Response to Vesicular Stomatitis Virus Vectors That Express Flagellin , 2013, Journal of Virology.
[154] E. Keller,et al. Mechanisms of Metastatic Tumor Dormancy , 2013, Journal of clinical medicine.
[155] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[156] J. Banchereau,et al. Dendritic-cell-based therapeutic cancer vaccines. , 2013, Immunity.
[157] R. Bei,et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. , 2012, Recent patents on anti-cancer drug discovery.
[158] S. Russell,et al. ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.
[159] C. Yun,et al. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF , 2011, Gene Therapy.
[160] D. Jocham,et al. Prostate Cancer Vaccines , 2012, BioDrugs.
[161] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[162] L. Lerescu,et al. Influence of Tumor Cell Culture Supernatants on Macrophage Functional Polarization: In Vitro Models of Macrophage-tumor Environment Interaction , 2011 .
[163] Aaron Fenster,et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans , 2011, Nature.
[164] P. Darcy,et al. Autoimmunity associated with immunotherapy of cancer. , 2011, Blood.
[165] L. Harrington,et al. Cytokines and the inception of CD8 T cell responses. , 2011, Trends in immunology.
[166] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[167] H. Young,et al. An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents , 2009, Annals of the New York Academy of Sciences.
[168] N. Stanietsky,et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.
[169] D. Green,et al. Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.
[170] E. Kremmer,et al. CD96 Interaction with CD155 via Its First Ig-like Domain Is Modulated by Alternative Splicing or Mutations in Distal Ig-like Domains* , 2009, Journal of Biological Chemistry.
[171] F. Hirsch,et al. MAGE A3 antigen-specific cancer immunotherapeutic. , 2009, Immunotherapy.
[172] L. Emens. Cancer vaccines: on the threshold of success , 2008, Expert opinion on emerging drugs.
[173] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[174] A. Simpson,et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. , 2007, Cancer research.
[175] H. Fang,et al. Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.
[176] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[177] M. Lai,et al. Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[178] Gang Wang,et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.
[179] R. Madan,et al. PSA-based vaccines for the treatment of prostate cancer , 2006, Expert review of vaccines.
[180] G. Zhu,et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.
[181] Ira Mellman,et al. Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.
[182] Circe Mesa,et al. Challenges facing adjuvants for cancer immunotherapy , 2004, Immunology and cell biology.
[183] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[184] G. Schwarzer,et al. Impact of granulocyte colony‐stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review , 2003, British journal of haematology.
[185] H. Pehamberger,et al. A genetically engineered influenza A virus with ras-dependent oncolytic properties. , 2001, Cancer research.
[186] B. Foster,et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.
[187] M. Tagawa. Cytokine therapy for cancer. , 2000, Current pharmaceutical design.
[188] K. Aozasa,et al. Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product1 , 2000, The Journal of Immunology.
[189] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[190] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[191] P. Romero,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.
[192] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[193] D. Scheinberg,et al. Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[194] Z. Eshhar,et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[195] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[196] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[197] S. Rosenberg,et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.
[198] L. Old,et al. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[199] P. Marrack,et al. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody , 1983, The Journal of experimental medicine.
[200] T. Taniguchi,et al. Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.
[201] Richard A. Miller,et al. RESPONSE OF CUTANEOUS T CELL LYMPHOMA TO THERAPY WITH HYBRIDOMA MONOCLONAL ANTIBODY , 1981, The Lancet.
[202] S. Rosenberg,et al. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. , 1980, Journal of immunology.
[203] F. Stevenson,et al. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. , 1977, Federation proceedings.
[204] R. Gallo,et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.
[205] R L Kassel,et al. An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[206] I. Hellstrom,et al. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[207] E. Haese. Treatment of Inoperable Cancer , 1902, Medizinische Klinik.
[208] James B. Murphy. FACTORS OF RESISTANCE TO HETEROPLASTIC TISSUE-GRAFTING : STUDIES IN TISSUE SPECIFICITY. III. , 1914 .